Brought to you by 
Baxter, Coherus pen biosimilars deal; terminated
30 Jan 2023
Executive Summary
Baxter International Inc. and biosimilars-focused Coherus BioSciences Inc. have teamed up to develop and commercialize a biosimilar formulation of etanercept in Europe, Canada, Brazil, and certain other markets. The deal term is ten years, subject to possible three-year extensions on a country-by-country basis.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxter, Coherus pen biosimilars deal; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice